Theravance Biopharma (TBPH) Operating Leases (2019 - 2026)

Theravance Biopharma (TBPH) has reported Operating Leases for 8 consecutive years, with $29.8 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Operating Leases fell 20.34% year-over-year to $29.8 million; the TTM figure through Mar 2026 stood at $29.8 million (down 20.34% YoY), while the FY2025 annual figure was $31.8 million, down 18.79% from the prior year.
• Operating Leases declined to $29.8 million in Q1 2026 per TBPH's latest filing, from $31.8 million in the prior quarter.
• Across five years, Operating Leases topped out at $51.4 million in Q3 2022 and bottomed at $29.8 million in Q1 2026.
• Historically, Operating Leases has averaged $41.3 million across 5 years, with a median of $42.4 million in 2024.
• Annual changes were most pronounced in 2024 — Operating Leases gained 0.18% — and 2026, when it declined 20.34%.
• Theravance Biopharma's Operating Leases stood at $45.4 million in 2022, then slipped by 0.38% to $45.2 million in 2023, then declined by 13.55% to $39.1 million in 2024, then dropped by 18.79% to $31.8 million in 2025, then fell by 6.32% to $29.8 million in 2026.
• Business Quant data shows TBPH's Operating Leases at $29.8 million in Q1 2026, $31.8 million in Q4 2025, and $33.7 million in Q3 2025.